Literature DB >> 6640516

Opioid antagonists inhibit the growth of metastatic murine neuroblastoma.

I S Zagon, P J McLaughlin.   

Abstract

Naltrexone (NTX), an opiate antagonist, had an inhibitory effect on the growth of S20 Y neuroblastoma (NB) in A/Jax mice. Daily injections of 0.1 mg/kg NTX resulted in a 69% tumor take, 70% delay in time prior to tumor appearance, and a 60% increase in median survival time. Inoculation of NB in control mice resulted in 100% tumor take within 15 days. The pattern and incidence of metastases of NTX and control mice were similar. These results show that NTX has antineoplastic activity, and suggests a role for the endogenous opioid system in neuro-oncogenic events.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6640516     DOI: 10.1016/0304-3835(83)90087-3

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  12 in total

Review 1.  Opioid growth factor and the treatment of human pancreatic cancer: a review.

Authors:  Ian S Zagon; Patricia J McLaughlin
Journal:  World J Gastroenterol       Date:  2014-03-07       Impact factor: 5.742

2.  Synthesis and evaluation of a ligand targeting the μ and δ opioid receptors for drug delivery to lung cancer.

Authors:  Guo Li; Philip S Low
Journal:  Bioorg Med Chem Lett       Date:  2016-06-28       Impact factor: 2.823

Review 3.  Naltrexone's Impact on Cancer Progression and Mortality: A Systematic Review of Studies in Humans, Animal Models, and Cell Cultures.

Authors:  Karina Liubchenko; Kevin Kordbacheh; Nika Khajehdehi; Tanja Visnjevac; Frederick Ma; James S Khan; Myles Storey; Alaa Abd-Elsayed; Ognjen Visnjevac
Journal:  Adv Ther       Date:  2020-12-18       Impact factor: 3.845

4.  A clinical study on the relationship between the pineal gland and the opioid system.

Authors:  P Lissoni; D Esposti; G Esposti; R Mauri; M Resentini; F Morabito; P Fumagalli; A Santagostino; G Delitala; F Fraschini
Journal:  J Neural Transm       Date:  1986       Impact factor: 3.575

5.  Opioid requirement, opioid receptor expression, and clinical outcomes in patients with advanced prostate cancer.

Authors:  Dylan Zylla; Brett L Gourley; Derek Vang; Scott Jackson; Sonja Boatman; Bruce Lindgren; Michael A Kuskowski; Chap Le; Kalpna Gupta; Pankaj Gupta
Journal:  Cancer       Date:  2013-09-16       Impact factor: 6.860

6.  Evidence for altered opioid activity in patients with cancer.

Authors:  P Lissoni; S Barni; F Paolorossi; S Crispino; F Rovelli; L Ferri; G Delitala; G Tancini
Journal:  Br J Cancer       Date:  1987-12       Impact factor: 7.640

7.  Morphine promotes cancer stem cell properties, contributing to chemoresistance in breast cancer.

Authors:  Dong-Ge Niu; Fei Peng; Wei Zhang; Zhong Guan; Hai-Dong Zhao; Jing-Lin Li; Kai-Li Wang; Ting-Ting Li; Yan Zhang; Fei-Meng Zheng; Fan Xu; Qian-Ni Han; Peng Gao; Qing-Ping Wen; Quentin Liu
Journal:  Oncotarget       Date:  2015-02-28

8.  Killing effect of methionine enkephalin on melanoma in vivo and in vitro.

Authors:  Dong-Mei Wang; Xue Jiao; Nicolas P Plotnikoff; Noreen Griffin; Rui-Qun Qi; Xing-Hua Gao; Feng-Ping Shan
Journal:  Oncol Rep       Date:  2017-08-24       Impact factor: 3.906

9.  Neuron-restrictive silencer factor-mediated downregulation of μ-opioid receptor contributes to the reduced morphine analgesia in bone cancer pain.

Authors:  Chao Zhu; Jun Tang; Tan Ding; Lei Chen; Wei Wang; Xiao-Peng Mei; Xiao-Tao He; Wen Wang; Li-Dong Zhang; Yu-Lin Dong; Zhuo-Jing Luo
Journal:  Pain       Date:  2017-05       Impact factor: 7.926

10.  COX-2 inhibitor celecoxib prevents chronic morphine-induced promotion of angiogenesis, tumour growth, metastasis and mortality, without compromising analgesia.

Authors:  M Farooqui; Y Li; T Rogers; T Poonawala; R J Griffin; C W Song; K Gupta
Journal:  Br J Cancer       Date:  2007-10-30       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.